Jul 15 2010
ALLOZYNE Inc. announced today the signing of a worldwide licensing agreement with The Scripps Research Institute. The agreement gives ALLOZYNE rights to a unique and powerful chemical reaction, developed by Nobel Laureate K. Barry Sharpless of Scripps Research, known as "Click chemistry." The novelty of this reaction comes from its ability to introduce two different molecular components and have them "click" together stably and irreversibly. Essentially, this reaction provides an easy, durable, reliable and cost-effective way of linking two distinct molecules together. ALLOZYNE's proprietary biociphering platforms, CAESAR and VIGENèRE, enable the site-specific incorporation of these "Click" components into virtually any protein and thereby provide a unique site at which any number of payloads can be securely attached. Considering the variety of moieties, which includes polymers, small molecules, antibodies, toxins, additional proteins and peptides, that the ALLOZYNE proprietary platform and Click chemistry are amenable to, this collaboration opens the door for building therapeutics not previously possible.
“Click is just like fastening the two distinct sides on the latch of a seatbelt”
"Click is just like fastening the two distinct sides on the latch of a seatbelt," stated Meenu Chhabra, President and CEO of ALLOZYNE. "Once the two are connected, you can be assured that they will not come undone. Thus, the capability to incorporate click chemistry into our biociphering platforms and create novel protein therapeutics is a powerful component of our armamentarium because it allows us to modify and improve virtually any protein therapeutic out there."
The agreement with Scripps Research provides ALLOZYNE with a license to apply Click chemistry for exclusive development in key therapeutic fields in addition to a non-exclusive license for diagnostic applications. The financial terms of the agreement were not disclosed.
SOURCE ALLOZYNE Inc.
BMI's influence on disease pathogenesis uncovered in new research